DOCSLIB.ORG

LGC Product List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LGC Product List Uni-Asia Scientific Instrument Company Limited - Your Worldwide Laboratory Supplies Sourcing Partner Email [email protected] Website www.uniasiahk.com Please browse through our product lists or send your enquiry to [email protected] for a quotation! Bulk pricing can always be discussed! LGC Standards Product List Code Discriptions AC-SE015.040.001 Drugs of substitution STM 3/10-A SE serum, 6 x 2.5ml AC-SE015.040.002 Drugs of substitution STM 1/11-A SE serum, 6 x 2.5ml AC-SE015.040.005.003TDM Benzodiazepine in serum, lyophilised BZF 3/10-A SE for AC-SE015.040.005.004TDM Benzodiazepine in serum, lyophilised BZF 3/10-B SE for AC-SE015.040.005.005TDM Benzodiazepine in serum, lyophilised BZF 1/11– A SE for AC-SE015.040.005.006TDM Benzodiazepine in serum, lyophilised BZF 1/11– B SE for BAM-K008 Diesel oil (ISO 9377-2, ISO 16703, EN 14039), 7ml BAM-K009 Lubricating oil (ISO 9377-2, ISO 16703, EN 14039), 7ml BAM-K010 Diesel Fuel/Lubricating Oil (1:1) (ISO 9377-2, ISO 16703, BAMSUS-1R Setting-up sample for sectrometric analysis of low alloyed BCR-010 Tin ore powder - Tin; 225g BCR-017A Copper - Sulfur and phosphorous, 370g BCR-017B Copper - Sulfur and phosphorous; 50g BCR-022A Copper (electrolytic tough pitch) - Oxygen; 42g BCR-022B Copper (electrolytic tough pitch) - Oxygen; 28g BCR-024B Titanium - Oxygen and nitrogen; 10g BCR-024C Titanium - Oxygen, nitrogen; 5g BCR-032 Moroccan phosphate rock - Trace elements; 100g BCR-033 Super-phosphate - Constituents; 100g BCR-038 Fly ash from pulverised coal - Trace elements; 5g BCR-039B Pyrex glass - Thermal conductivity; board BCR-039C Pyrex glass - Thermal conductivity; board BCR-046 Benzo[b]chrysene; 100mg BCR-047 Benzo[b]fluoranthene; 100mg BCR-048R Benzo[k]fluoranthene; 10mg BCR-049 Benzo[j]fluoranthene; 100mg BCR-050 Benzo[e]pyrene; 100mg BCR-052 Benzo[ghi]perylene; 100mg BCR-054R Copper - Oxygen; 42g BCR-055 Lead (refined) - Oxygen; 71g Uni-Asia Scientific Instrument Company Limited - Your Worldwide Laboratory Supplies Sourcing Partner Email [email protected] Website www.uniasiahk.com Please browse through our product lists or send your enquiry to [email protected] for a quotation! Bulk pricing can always be discussed! LGC Standards Product List Code Discriptions BCR-058 Copper (continuous cast) - Oxygen; 17g BCR-059A Titanium alloy Ti6Al4V - Oxygen and nitrogen; 21g BCR-059B Titanium alloy Ti6Al4V - Oxygen and nitrogen; 5g BCR-060 Aquatic plant (Lagarosiphon major) - Trace elements, 25g BCR-063R Skimmed milk powder - Major and trace elements; 50g BCR-066 Quartz - Stokes' diameter; 10g BCR-067 Quartz - Stokes' diameter; 10g BCR-068 Quartz - Volume diameter; 100g BCR-069 Quartz - Stokes' diameter; 10g BCR-070 Quartz - Stokes' diameter; 10g BCR-074A Electrolytic copper - Trace elements; disc BCR-077R Chrysene, 1-methyl; 10mg BCR-078R Chrysene, 2-methyl; 10mg BCR-079R Chrysene, 3-methyl; 10mg BCR-080R Chrysene, 4-methyl; 10mg BCR-081R Chrysene, 5-methyl; 10mg BCR-089 Titanium alloy Ti 6Al 4V - Aluminium, Vanadium; disc BCR-090A Titanium - Impurities; disc BCR-090B Titanium - Impurities; 25g BCR-091 Anthanthrene; 100mg BCR-092 10-Azabenzo[a]pyrene; 100mg BCR-093R Benzo[a]anthracene, 1-methyl; 10mg BCR-094 Dibenzo[a,c]anthracene; 100mg BCR-095 Dibenzo[a,j]anthracene; 100mg BCR-096 Dibenzo[a,l]pyrene, 100MG BCR-097 Benzo[a]fluoranthene; 100mg BCR-099 Nickel - Oxygen and nitrogen; 50g BCR-100 Beech leaves - Trace elements, 30g BCR-102 Tungsten carbide powder - Oxygen; 2-3g BCR105 Gas oil (0.363% S) Uni-Asia Scientific Instrument Company Limited - Your Worldwide Laboratory Supplies Sourcing Partner Email [email protected] Website www.uniasiahk.com Please browse through our product lists or send your enquiry to [email protected] for a quotation! Bulk pricing can always be discussed! LGC Standards Product List Code Discriptions BCR-105 Gas oil - Sulfur; 25 g BCR-106 Gas oil - Sulfur; 25g BCR-107 Gas oil - Sulfur; 25g BCR-109 Zinc ore concentrate - Trace elements; 200g BCR-110 Zinc ore concentrate - Trace elements; 200g BCR-113 Potassium chloride - Elemental composition; 100g BCR-114 Potassium sulphate - Elemental composition; 100g BCR-115 Animal feed - Pesticides, 30g BCR-116 Limestone powders; 3.2kg BCR-121 Wholewheat flour - Vitamins; 50g BCR-122 Margarine - Vitamins, 200G BCR-123A Ethanol - D/H isotopic determination; 3tubes BCR-123B Ethanol - D/H isotopic determination; 3tubes BCR-126A Lead glass - Constituents; 300g BCR-129 Hay powder - Trace elements; 30g BCR-130 Quartz - Volume diameter; 50g BCR-131 Quartz - Volume diameter; 200g BCR-132 Quartz - Volume diameter; 700g BCR-133 Dibenzo[a,e]pyrene, 100MG BCR-134 Benzo[c]phenanthrene; 100mg BCR-136R Benzo[b]naphtho[2,3-d]thiophene; 10mg BCR-137R Benzo[b]naphtho[1,2-d]thiophene; 10mg BCR-138 Dibenzo[a,h]anthracene; 100mg BCR-139 Benzo[ghi]fluoranthene; 100mg BCR-140 Benzo[c]chrysene; 100mg BCR-142R Light sandy soil - Trace elements; 40g BCR-143R Sewage sludge amended soil - Major and trace elements; 40g BCR-145R Sewage sludge (mixed origin) - Trace elements; 40g BCR-146R Sewage sludge (industrial origin) - Trace elements; 40g BCR-150 Spiked skimmed milk powder - Trace elements; 23g Uni-Asia Scientific Instrument Company Limited - Your Worldwide Laboratory Supplies Sourcing Partner Email [email protected] Website www.uniasiahk.com Please browse through our product lists or send your enquiry to [email protected] for a quotation! Bulk pricing can always be discussed! LGC Standards Product List Code Discriptions BCR-151 Spiked skimmed milk powder - Trace elements; 23g BCR-152 Dibenzo[a,i]acridine; 20mg BCR-153R Dibenzo[a,h]acridine; 10mg BCR-154 Dibenzo[a,j]acridine; 100mg BCR-155 Dibenzo[a,c]acridine, 100mg BCR-156R Dibenzo[c,h]acridine; 10mg BCR-157 Benzo[a]acridine; 100mg BCR-158 Benzo[c]acridine; 100mg BCR-159 Dibenzo[a,h]pyrene, 100MG BCR-160R Fluoranthene; 10mg BCR-162R Soya-maize oil blend - Fatty acids; 5.5g BCR-163 Beef/pork fat blend - Fatty acids, 2 amp/pk BCR-165 Latex spheres, nominal 2 μ; vial BCR-166 Latex spheres, nominal 4.8 μ; vial BCR-167 Latex spheres, nominal 9.6 μ; vial BCR-168 Picene; 10mg BCR-169 alpha-Alumina - Specific surface area (BET); 60g BCR-170 alpha-Alumina - Specific surface area (BET); 60g BCR-171 Alumina - Specific surface area (BET); 50g BCR-172 Quartz - Specific surface area (BET); 10g BCR-173 Titania - Specific surface area (BET); 46g BCR-175 Tungsten - Specific surface area (BET); 200g BCR-176R Fly ash - Trace elements; 40g BCR-177R Pyrene; 10mg BCR-178 Calcium ammonium nitrate - Elemental composition; 100g BCR-179 Urea - Composition; 100g BCR-185R Bovine liver - Trace elements, 15G BCR-187 Natural milk powder - Pesticides; 20g BCR-188 Milk powder (spiked) - Pesticides; 20g Uni-Asia Scientific Instrument Company Limited - Your Worldwide Laboratory Supplies Sourcing Partner Email [email protected] Website www.uniasiahk.com Please browse through our product lists or send your enquiry to [email protected] for a quotation! Bulk pricing can always be discussed! LGC Standards Product List Code Discriptions BCR-191 Brown bread - Trace elements; 40g BCR-261T Tantalum pentoxide on tantalum foil; 2x4foil BCR-262R Defatted peanut meal (blank) - Aflatoxin B1; 100g BCR-263R Defatted peanut meal - Aflatoxin B1, B2 and G1, 100G BCR-264 Defatted peanut meal (high level) - Aflatoxin B1, 150G BCR-265 Dibenzo[a,e]fluoranthene; 20mg BCR-266 7H-Dibenzo[c,g]carbazole; 20mg BCR-267 Indeno[1,2,3-cd]fluoranthene; 20mg BCR-269 Chrysene; 20mg BCR-270 Triphenylene; 20mg BCR-271 Benzo[a]anthracene; 20mg BCR-272 Coronene, 20mg BCR-273 Single cell protein; 10g BCR-274 Single cell protein - Trace elements; 10g BCR-275 Zirconium alloy Zircaloy-4 - Oxygen, nitrogen and carbon; 9g BCR-276 Zirconium alloy Zircaloy-4 BCR-277R Estuarine sediment - Trace elements; 40g BCR-279 Sea lettuce (ulva lactuca) - Trace elements, 35g BCR-280R Lake sediment - Trace elements; 30g BCR-286A Lead (electrolytically refined) - Trace elements; 600g BCR-286B Lead (electrolytically refined) - Trace elements; 160g BCR-287A Lead (thermally refined) -Trace elements; 600g BCR-287B Lead (thermally refined) -Trace elements; 160g BCR-288B Lead with added impurities - Trace elements; 160g BCR-289 2,4'-Dichlorobiphenyl (PCB 8); 25mg BCR-290 2,3,3'-Trichlorobiphenyl (PCB 20); 25mg BCR-291 2,4,4'-Trichlorobiphenyl (PCB 28), 25MG BCR-293 2,2',5,5'-Tetrachlorobiphenyl (PCB 52); 25mg BCR-296 2,2',3,4,4',5'-Hexachlorobiphenyl (PCB 138); 25mg BCR-297 2,2',4,4',5,5'-Hexachlorobiphenyl (PCB 153); 25mg Uni-Asia Scientific Instrument Company Limited - Your Worldwide Laboratory Supplies Sourcing Partner Email [email protected] Website www.uniasiahk.com Please browse through our product lists or send your enquiry to [email protected] for a quotation! Bulk pricing can always be discussed! LGC Standards Product List Code Discriptions BCR-298 2,2',3,4,4',5,5'-Heptachlorobiphenyl (PCB 180); 25mg BCR-301(RM) Mullite; 50g BCR-302 Microcrystalline Cellulose BCR-305 Pyrene, 1-nitro; 10mg BCR-306 Naphthalene, 1-nitro; 10mg BCR-307 Naphthalene, 2-nitro; 10mg BCR-308 Anthracene, 9-nitro; 10mg BCR-309 Chrysene, 6-nitro; 10mg BCR-310 Fluoranthene, 3-nitro; 10mg BCR-311 Benzo[a]pyrene, 6-nitro; 10mg BCR-312 Naphtho[2,1-b]furan, 2-nitro-7-methoxy; 10mg BCR-318 Titanium - Hydrogen; 20g BCR-320R Channel sediment - Trace elements; 40g BCR-321 Unalloyed zinc - Trace elements; 0.7kg BCR-326 Unalloyed zinc - Trace elements; 0.7kg BCR-327 Unalloyed zinc - Trace elements; 0.7kg BCR-331 Low volatile steam coal - Sulfur; 20g BCR-332 High volatile industrial coal - Sulfur; 20g BCR-333
Load more

Recommended publications
  • US 2014/0116112 A1 HUMPHREY Et Al
    US 201401 16112A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0116112 A1 HUMPHREY et al. (43) Pub. Date: May 1, 2014 (54) METHODS FOR DETERMINING THE Publication Classification PRESENCE OR ABSENCE OF CONTAMINANTS IN A SAMPLE (51) Int. Cl. GOIN30/72 (2006.01) (71) Applicant: K & D LABORATORIES, INC., Lake (52) U.S. Cl. Oswego, OR (US) CPC .................................. G0IN30/7206 (2013.01) USPC ......................................................... T3/23.37 (72) Inventors: David Kent HUMPHREY, Reno, NV (US); Nicholas Joseph GEISE, Portland, OR (US) (57) ABSTRACT (73) Assignee: K & D LABORATORIES, INC., Lake Oswego, OR (US) Methods are provided for rapidly determining the presence or absence of large numbers of contaminants in a test sample, (21) Appl. No.: 13/830,388 Such as a raw material intended for use in the preparation of a nutraceutical. The disclosed methods employ gas chromatog (22) Filed: Mar 14, 2013 raphy-mass spectrometry techniques together with the spe cific use of software in combination with a database to ana Related U.S. Application Data lyze data collected after ionization of the sample and (60) Provisional application No. 61/718,607, filed on Oct. determine the presence or absence of the contaminants in the 25, 2012. sample. US 2014/01161 12 A1 May 1, 2014 METHODS FOR DETERMINING THE 0007. In one embodiment, methods for detecting the pres PRESENCE OR ABSENCE OF ence or absence of a plurality of contaminants in a sample are CONTAMINANTS IN A SAMPLE provided, such methods comprising: (a) extracting the sample with a water-miscible solvent in the presence of a high con REFERENCE TO RELATED APPLICATIONS centration of salts to provide a sample extract; (b) shaking and centrifuging the sample extract to provide a Supernatant; (c) 0001.
    [Show full text]
  • Factors Influencing Pesticide Resistance in Psylla Pyricola Foerster and Susceptibility Inits Mirid
    AN ABSTRACT OF THE THESIS OF: Hugo E. van de Baan for the degree ofDoctor of Philosopbv in Entomology presented on September 29, 181. Title: Factors Influencing Pesticide Resistance in Psylla pyricola Foerster and Susceptibility inits Mirid Predator, Deraeocoris brevis Knight. Redacted for Privacy Abstract approved: Factors influencing pesticide susceptibility and resistance were studied in Psylla pyricola Foerster, and its mirid predator, Deraeocoris brevis Knight in the Rogue River Valley, Oregon. Factors studied were at the biochemical, life history, and population ecology levels. Studies on detoxification enzymes showed that glutathione S-transferase and cytochrome P-450 monooxygenase activities were ca. 1.6-fold higherin susceptible R. brevis than in susceptible pear psylla, however, esterase activity was ca. 5-fold lower. Esterase activity was ca. 18-fold higher in resistant pear psylla than in susceptible D. brevis, however, glutathione S-transferase and cytochrome P-450 monooxygenase activities were similar. Esterases seem to be a major factor conferring insecticideresistance in P. Pvricola. Although the detoxification capacities of P. rivricola and D. brevis were quite similar, pear psylla has developed resistance to many insecticides in the Rogue River Valley, whereas D. brevis has remained susceptible. Biochemical factors may be important in determining the potential of resistance development, however, they are less important in determining the rate at which resistance develops. Computer simulation studies showed that life history and ecological factors are probably of greater importancein determining the rate at which resistance develops in P. pvricola and D. brevis. High fecundity and low immigration of susceptible individuals into selected populations appear to be major factors contributing to rapid resistance development in pear psylla compared with D.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Anabolic-Androgenic Steroids in Horses: Natural Presence and Underlying Biomechanisms
    ANABOLIC-ANDROGENIC STEROIDS IN HORSES: NATURAL PRESENCE AND UNDERLYING BIOMECHANISMS Anneleen Decloedt Dissertation submitted in the fulfilment of the requirements for the degree of Doctor of philosophy (PhD) in Veterinary Sciences, Faculty of Veterinary Medicine, Ghent University PROMOTER Prof. dr. ir. Lynn Vanhaecke Ghent University, Faculty of Veterinary Medicine Department of Veterinary Public Health and Food Safety Laboratory of Chemical Analysis MEMBERS OF THE READING COMMITTEE Prof. dr. James Scarth HFL Sport Science, Cambridgeshire, United-Kingdom Prof. dr. Peter Van Eenoo Ghent University, DoCoLab, Zwijnaarde, Belgium Prof. dr. Ann Van Soom Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium MEMBERS OF THE EXAMINATION COMMITTEE Dr. Ludovic Bailly-Chouriberry Laboratoires des Courses Hippiques, Verrières-le-Buisson, France Dr. Leen Van Ginkel Wageningen University, RIKILT, Wageningen, The Netherlands Prof. dr. Myriam Hesta Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium This work was funded by the Fédération Nationale des Courses Françaises (via the Laboratoire des Courses Hippiques) and executed at the Laboratory of Chemical Analysis (Faculty of Veterinary Medicine, Ghent University, Merelbeke). The author and the promoter give the authorisation to consult and to copy parts of this work for personal use only. Every other use is subject to the copyright laws. Permission to reproduce any material contained in this work should be obtained from the author. “The universe is full of magic, Just patiently waiting for our wits to grow sharper” TABLE OF CONTENTS TABLE OF CONTENTS Chapter I – General Introduction 1 1. Steroids 3 1.1 Chemical structure 1.2 (Steroid) hormones and their role in the endocrine system 1.3 Biosynthesis of steroid hormones 1.4 Anabolic-androgenic steroids (AAS) 1.5 Synthesis and absorption of the steroid precursor cholesterol 2.
    [Show full text]
  • MICROCOMP Output File
    108TH CONGRESS 2D SESSION S. 2195 AN ACT To amend the Controlled Substances Act to clarify the defini- tion of anabolic steroids and to provide for research and education activities relating to steroids and steroid precursors. 1 Be it enacted by the Senate and House of Representa- 2 tives of the United States of America in Congress assembled, 3 SECTION 1. SHORT TITLE. 4 This Act may be cited as the ‘‘Anabolic Steroid Con- 5 trol Act of 2004’’. 2 1 SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES 2 ACT. 3 (a) DEFINITIONS.—Section 102 of the Controlled 4 Substances Act (21 U.S.C. 802) is amended— 5 (1) in paragraph (41)— 6 (A) by realigning the margin so as to align 7 with paragraph (40); and 8 (B) by striking subparagraph (A) and in- 9 serting the following: 10 ‘‘(A) The term ‘anabolic steroid’ means any drug or 11 hormonal substance, chemically and pharmacologically re- 12 lated to testosterone (other than estrogens, progestins, 13 corticosteroids, and dehydroepiandrosterone), and 14 includes— 15 ‘‘(i) androstanediol— 16 ‘‘(I) 3β,17β-dihydroxy-5α-androstane; and 17 ‘‘(II) 3α,17β-dihydroxy-5α-androstane; 18 ‘‘(ii) androstanedione (5α-androstan-3,17- 19 dione); 20 ‘‘(iii) androstenediol— 21 ‘‘(I) 1-androstenediol (3β,17β-dihydroxy- 22 5α-androst-1-ene); 23 ‘‘(II) 1-androstenediol (3α,17β-dihydroxy- 24 5α-androst-1-ene); 25 ‘‘(III) 4-androstenediol (3β,17β-dihydroxy- 26 androst-4-ene); and †S 2195 ES 3 1 ‘‘(IV) 5-androstenediol (3β,17β-dihydroxy- 2 androst-5-ene); 3 ‘‘(iv) androstenedione— 4 ‘‘(I) 1-androstenedione ([5α]-androst-1-en- 5 3,17-dione);
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Current Strategies of Cancer Chemoprevention: 13Th Sapporo Cancer Seminar
    ICANCER RESEARCH54, 3315—3318,June15, 19941 Meeting Report Current Strategies of Cancer Chemoprevention: 13th Sapporo Cancer Seminar The broad concept of chemoprevention applies to the prevention of either antimutagenic or antimitogenic. Antioxidants, because of their clinical cancer by the administration of pharmaceuticals or dietary similar mechanism of action, have been grouped separately as a third constituents. In recent years there has been a rapid expansion of basic class. Antioxidants are both antimutagenic and antimitogenic. research on mechanisms of chemoprevention, and more and more candidate compounds are entering clinical trials. It is therefore timely Clinical Trials of Chemopreventive Agents that the subject of the 13th Sapporo Cancer Seminar held on July 6—9, 1993, was “CurrentStrategies of Cancer Chemoprevention.― The Head and Neck. Dr. W-K. Hong (University of Texas M. D. Seminar was organized by Drs. H. Fujiki, H. Kobayashi, L. W. Anderson Cancer Center, Houston, TX) reviewed the successful use Wattenberg, C. W. Boone, and 0. J. Kelloff. of 13-cRA against the development of upper aerodigestive tract neo plasia. In trials in human oral premalignancy, or leukoplakia, 13-cPA Chemoprevention by Minor Nonnutrient Constituents achieved a significant objective response rate of 67% (3). In an of the Diet adjuvant trial to prevent second primary tumors in patients initially “cured―ofhead and neck squamous cell carcinoma, 13-cPA signifi Dr. L. Wattenberg (University of Minnesota, Minneapolis, MN) cantly reduced the high incidence of these usually fatal second ma described the growing awareness in recent years that dietary nonnu lignancies (4). Moderate to severe side effects of 13-cPA include: skin trient compounds can have extremely important effects on the conse dryness (63% versus 8% placebo); cheilitis (24% versus 2% placebo); quences of exposure to carcinogens, drugs, and an assortment of other and conjunctivitis (18% versus 8% placebo).
    [Show full text]
  • OSPAR Background Document on Methoxychlor ______
    Hazardous Substances Series --------------------------------------------------------------------------------------------------------------------- Methoxychlor1 OSPAR Commission 2002 (2004 Update) 1 Secretariat’s note: A review statement on methoxychlor (Publication 352d/2008) was adopted in 2008, highlighting new developments since the adoption of the Background Document. OSPAR Commission, 2002: OSPAR Background Document on Methoxychlor _______________________________________________________________________________________________________ The Convention for the Protection of the Marine Environment of the North-East Atlantic (the “OSPAR Convention”) was opened for signature at the Ministerial Meeting of the former Oslo and Paris Commissions in Paris on 22 September 1992. The Convention entered into force on 25 March 1998. It has been ratified by Belgium, Denmark, Finland, France, Germany, Iceland, Ireland, Luxembourg, Netherlands, Norway, Portugal, Sweden, Switzerland and the United Kingdom and approved by the European Community and Spain. La Convention pour la protection du milieu marin de l'Atlantique du Nord-Est, dite Convention OSPAR, a été ouverte à la signature à la réunion ministérielle des anciennes Commissions d'Oslo et de Paris, à Paris le 22 septembre 1992. La Convention est entrée en vigueur le 25 mars 1998. La Convention a été ratifiée par l'Allemagne, la Belgique, le Danemark, la Finlande, la France, l’Irlande, l’Islande, le Luxembourg, la Norvège, les Pays-Bas, le Portugal, le Royaume-Uni de Grande Bretagne et d’Irlande du Nord, la Suède et la Suisse et approuvée par la Communauté européenne et l’Espagne. © OSPAR Commission, 2002. Permission may be granted by the publishers for the report to be wholly or partly reproduced in publications provided that the source of the extract is clearly indicated. © Commission OSPAR, 2002.
    [Show full text]
  • (A) Sources, Including As Appropriate (Provide Summary Information
    UNEP/POPS/POPRC.1/4 Format for submitting pursuant to Article 8 of the Stockholm Convention the information specified in Annex E of the Convention Introductory information Name of the submitting Party/observer NGO Observer: Pesticide Action Network on behalf of the International POPs Elimination Network (IPEN) Contact details Clare Butler Ellis PhD, M.Inst.P, C.Env. Pesticide Action Network UK [email protected] Joseph DiGangi, PhD Environmental Health Fund +001-312-566-0985 [email protected] Chemical name Chlordecone Chemical name: 1,1a,3,3a,4,5,5,5a,5b,6-decachloro-octahydro-1,3,4-metheno-2H- cyclobuta[cd]pentalen-2-one CAS=143-50-0 Common trade names: GC 1189, Kepone, Merex Synonyms: Chlordecone, Chlordecone Kepone, Decachloroketone, Decachlorooctahydro-1,3,4-metheno-2H-cyclobuta(cd)pentalen-2-one, Decachloropentacyclo(5.3.0.0.0.0 2,6,4,10,5,9)decane-3-one, Decachlorotetracyclodecanone decachlorooctahydro- , Date of submission 27 January 2006 (a) Sources, including as appropriate (provide summary information and relevant references) (i) Production data: Quantity 1 “Chlordecone is no longer produced commercially in the United States. Between 1951 and 1975, approximately 3.6 million pounds (1.6 million kg) of chlordecone were produced in the United States (Epstein 1978). During this period, Allied Chemical Annex E information on chlordecone 1 UNEP/POPS/POPRC.1/4 Company produced approximately 1.8 million pounds (816,500 kg) of chlordecone at plants in Claymont, Delaware; Marcus Hook, Pennsylvania and Hopewell, Virginia. In 1974, because of increasing demand for chlordecone and a need to use their facility in Hopewell, Virginia, for other purposes, Allied Chemical transferred its chlordecone manufacturing to Life Sciences Products Company (EPA 1978b).
    [Show full text]
  • New Aspects for the Treatment of Cardiac Diseases Based on the Diversity of Functional Controls on Cardiac Muscles: Acute Effect
    J Pharmacol Sci 109, 334 – 340 (2009)3 Journal of Pharmacological Sciences ©2009 The Japanese Pharmacological Society Forum Minireview New Aspects for the Treatment of Cardiac Diseases Based on the Diversity of Functional Controls on Cardiac Muscles: Acute Effects of Female Hormones on Cardiac Ion Channels and Cardiac Repolarization Junko Kurokawa1,*, Takeshi Suzuki2, and Tetsushi Furukawa1 1Department of Bio-informational Pharmacology, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan 2Faculty of Pharmacy, Division of Basic Biological Sciences, Keio University, 1-5-30 Shiba-koen, Minato-ku, Tokyo 105-8512, Japan Received October 16, 2008; Accepted December 6, 2008 Abstract. Regulation of cardiac ion channels by sex hormones accounts for gender differences in susceptibility to arrhythmias associated with QT prolongation (TdP). Women are more prone to develop TdP than men with either congenital or acquired long-QT syndrome. The risk of drug- induced TdP varies during the menstrual cycle, suggesting that dynamic changes in levels of ovarian steroids, estradiol and progesterone, have cyclical effects on cardiac repolarization. Although increasing evidence suggests that the mechanism of this involves effects of female hormones on cardiac repolarization, it has not been completely clarified. In addition to well- characterized transcriptional regulation of cardiac ion channels and their modifiers through nuclear hormone receptors, we recently reported that physiological levels of female hormones modify functions of cardiac ion channels in mammalian hearts. In this review, we introduce our recent findings showing that physiological levels of the two ovarian steroids have opposite effects on cardiac repolarization. These findings may explain the dynamic changes in risk of arrhythmia in women during the menstrual cycle and around delivery, and they provide clues to avoiding potentially lethal arrhythmias associated with QT prolongation.
    [Show full text]